BGI Genomics today announces that the DNA Methylation Detection Kit for Human SDC2, ADHFE1 and PPP2R5C Genes (Real-Time PCR) has been CE marked. The kit can detect the methylation of SDC2, ADHFE1 and PPP2R5C genes in human fecal samples.

According to the Global Cancer 2020 (GLOBOCAN) statistics, there are about 19.3 million new cases of colorectal cancer each year, accounting for 10.0 percent of all new cancer cases. About 935,000 colorectal cancer deaths occur each year, accounting for 9.4 percent of all cancer deaths.

Abnormality of DNA methylation modification is closely related to the occurrence and development of cancer. This newly CE marked kit detects abnormal methylation of SDC2, ADHFE1 and PPP2R5C genes in stool DNA, which are highly specific markers for colorectal cancer cells. The kit is intended to be used as a non-invasive test to aid diagnosis of patients who are recommended by clinicians to receive diagnostic colonoscopy.